L Vellekoop

584 total citations
17 papers, 452 citations indexed

About

L Vellekoop is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, L Vellekoop has authored 17 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 7 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in L Vellekoop's work include Hematopoietic Stem Cell Transplantation (10 papers), Acute Myeloid Leukemia Research (7 papers) and Cancer therapeutics and mechanisms (3 papers). L Vellekoop is often cited by papers focused on Hematopoietic Stem Cell Transplantation (10 papers), Acute Myeloid Leukemia Research (7 papers) and Cancer therapeutics and mechanisms (3 papers). L Vellekoop collaborates with scholars based in United States and Germany. L Vellekoop's co-authors include Gary Spitzer, K. B. McCredie, D. S. Verma, Karel A. Dicke, J. P. Hester, L. J. Peters, A. Zander, A R Zander, Hagop M. Kantarjian and Michael J. Keating and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

L Vellekoop

17 papers receiving 397 citations

Peers

L Vellekoop
Comparison fields: 5 of 45
  • Hematology 307
  • Oncology 141
  • Genetics 112
  • Public Health, Environmental and Occupational Health 80
  • Molecular Biology 67
Replace Phillips Gl with:
Phillips Gl Canada
D. S. Verma United States
LC Lasky United States
M Shtalrid Israel
B Clarkson United States
G. P. Clein United Kingdom
Bjarne Anker Jensen Denmark
Bloomfield Cd United States
R. Vimercati Italy
Anne Stucki Germany
Phillips Gl Canada View profile →
Citations per field, relative to L Vellekoop
L Vellekoop · 1×
Citations per year, relative to L Vellekoop
L Vellekoop · 1×

Countries citing papers authored by L Vellekoop

Since Specialization
Citations

This map shows the geographic impact of L Vellekoop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Vellekoop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Vellekoop more than expected).

Fields of papers citing papers by L Vellekoop

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Vellekoop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Vellekoop. The network helps show where L Vellekoop may publish in the future.

Co-authorship network of co-authors of L Vellekoop

This figure shows the co-authorship network connecting the top 25 collaborators of L Vellekoop. A scholar is included among the top collaborators of L Vellekoop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Vellekoop. L Vellekoop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
# Work Indexed citations
1
Piperazinedione plus total body irradiation: an alternative preparative regimen for allogeneic bone marrow transplantation in advanced phases of chronic myelogenous leukemia.
4
2 16
3
Potential drugs for elimination of acute lymphatic leukemia cells from autologous bone marrow.
9
4 8
5 79
6
The role of autologous bone marrow transplantation in various malignancies.
32
7 49
8
Leukemic cell colony formation in soft agar by bone marrow cells and peripheral blood cells from untreated acute leukemia patients.
8
9
Medulloblastoma and neuroblastoma in adults.
5
10
High-dose AMSA and bone marrow rescue in patients with solid tumors.
9
11
High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia.
1
12
Autologous bone marrow transplantation in neoplasia.
11
13
Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
14
14 40
15 51
16 112
17
Myelopoietic enhancement by immunoadjuvants: in vitro studies for their rational use in neutropenic patients.
4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026